FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial

Global Bioengineered Protein Drugs Market to Reach USD 521.3bn by 2027, According to Research and Markets

Viking Therapeutics reports positive results from Phase 1 clinical trial of VK2735 for potential treatment of metabolic disorders

CSL opens Massachusetts research and development centre

BJ Bioscience signs clinical trial collaboration and supply agreement with Merck

DermBiont Touts Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel

Athersys Reports on Type B Meeting with the US FDA

FSD Pharma's Australian Entity Receives Approval to Proceed with Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder

Incyte receives Japanese approval for Pemazyre to treat myeloid/lymphoid neoplasms

Pharming Group's Joenja receives FDA approval to treat APDS

Ionis Pharmaceuticals announces positive topline results from eplontersen Phase three NEURO-TTRansform study

European Commission Grants Orphan Designation for iECURE's Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase Deficiency

Josep Bassaganya-Riera Launches NImmune Biopharma

ONO Pharma USA's Tirabrutinib (ONO-4059) receives FDA Orphan Drug Designation

Mitsubishi Tanabe Pharma America completes enrolment for global Phase 3b study of RADICAVA ORS (edaravone) in ALS